Necrotising pneumonia in young, previously healthy patients due to Panton-Valentine leucocidin (PVL) producing Staphylococcus aureus has been increasingly recognised. PVL pneumonia is often associated with infl uenza co-infection and high mortality. This case report describes the successful management of the fi rst documented paediatric case of a previous healthy adolescent who developed necrotising pneumonia due to community-acquired methicillin-resistant (CA-MRSA) clone USA300 with pandemic infl uenza A (H1N1) co-infection, and highlights the importance of early recognition and initiation of appropriate therapy for this potentially fatal co-infection. PCR remains the gold standard to diagnose pandemic H1N1 since it may not be detected by rapid antigen tests. Bacterial necrotising pneumonia should be suspected in those presenting with worsening fl u-like symptoms and clinical and/ or radiological evidence of PVL infection (multifocal infi ltrates, effusion and cavitation). These patients may benefi t from the administration of toxin neutralising agents. In light of the current H1N1 pandemic, healthcare professionals will be increasingly confronted with this clinical scenario.
BACKGROUND
Necrotising pneumonia in young, previously healthy patients due to Panton-Valentine leucocidin (PVL) producing Staphylococcus aureus has been increasingly recognised. PVL pneumonia is often associated with infl uenza co-infection and mortalities of over 50% have been reported. 1 2 In the USA increasing numbers of cases of this condition have been reported in recent years, mostly related to community-acquired methicillin-resistant (CA-MRSA) USA300 clone, which may have an epidemic character due to the presence of the arginine catabolic mobile element (ACME). 3 In contrast, in Europe most of the reported PVL cases are due to more genetically diverse communityacquired methicillin-susceptible S aureus strains. 2 Optimal therapy for this potentially lethal disease has not yet been established. Vancomycin remains the mainstay of treatment for invasive MRSA infections, but concerns regarding its effectiveness in pulmonary infection are increasing. 1 Based on in vitro studies, combination therapy with toxin-suppressing agents such as clindamycin have been advocated for this clinical condition. 4 The case reported below describes the successful management of the fi rst documented paediatric case of a previous healthy adolescent who developed necrotising pneumonia due to CA-MRSA clone USA300 with pandemic infl uenza A (H1N1) co-infection.
CASE PRESENTATION
A 12-year-old previously healthy adolescent developed increased respiratory symptoms and fever while fl ying to Spain from California, USA. He was admitted to a district hospital and a chest x-ray showed right pleural effusion and consolidation of both lower lobes. He was feverish and blood tests revealed a leucocyte count of 5.9×10 9 /l (neutrophils 76%) and C-reactive protein of 206 mg/l. Initial therapy consisted of ceftriaxone, vancomycin and clarithromycin and the patient was transferred into our care on day 5 of his illness. On admission, his temperature was 38.5ºC, he had moderate respiratory distress (respiratory rate 40/min, oxygen saturation 92% in 1 l/min O 2 via a nasal cannula) and a chest x-ray showed a small spontaneous left pneumothorax (fi gure 1a). Antibiotic therapy was continued with vancomycin, while clindamycin was added to optimise treatment for possible CA-MRSA pneumonia. MRSA (sensitive to vancomycin (minimum inhibition concentration 0.5 μg/ml) and clindamycin (D-test negative)) were cultured from pleural fl uid culture on day 7. This MRSA strain was further characterised as the USA300 clone as it was positive for PVL and ACME.
A rapid fl u (Directigen Flu A+B) test from nasopharyngeal aspirate was negative on days 5 and 7 of disease, however pandemic H1N1 infl uenza was diagnosed by PCR on day 7 and oseltamivir was added to the patient's treatment. Despite this he developed increasing respiratory failure and so was transferred to the paediatric intensive care unit on day 13 and ventilated for 7 days. He required video-assisted thorascopic surgery and chest tube insertion for bilateral pleural empyema and pneumothorax. Linezolid was substituted for vancomycin on day 11 because of low vancomycin trough levels (4.2 mg/l despite using high doses of vancomycin of 60 mg/kg/day) and poor clinical response. Pleural cultures remained positive until day 11. The patient became apyrexial by day 23, while his infection markers continued to improve. Linezolid was switched to oral therapy on day 27 to complete a total of 3 weeks of treatment. The patient was discharged on day 28 in good clinical
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and Prevention have recently described the characteristics of 36 children who died of pandemic H1N1 infl uenza, fi ve of whom died as a result of S aureus co-infection (MRSA was isolated from three patients and MSSA from two). 8 Bacterial necrotising pneumonia due to S aureus, Streptococcus pyogenes or Streptococcus pneumoniae should be suspected in previous healthy patients presenting with worsening fl u-like symptoms and clinical (low white cell count, raised C-reactive protein) and/or radiological evidence of this disease (multifocal infi ltrates, pleural effusions and cavitation). These patients may benefi t from toxin neutralising agents such as clindamycin. 4 
CONCLUSION
In the current H1N1 pandemic it is of great importance that this potentially fatal co-infection is quickly recognised and appropriate management initiated, especially as it generally manifests in previous healthy young patients. A diagnosis of pandemic H1N1 should be made using PCR as rapid antigen tests for infl uenza A may be falsely negative and appropriate therapy may thus be delayed or not administered at all. 9 Based on experience from the 1918 and 1957 infl uenza pandemics and the epidemic potential of the MRSA USA300 clone, it is likely that the general practitioner as well as specialist hospital doctors will now be increasingly confronted with this clinical scenario, including those in countries with a low prevalence of CA-MRSA, due to globalisation. condition, although chest x-ray showed bilateral multiple small pneumatoceles with residual pleural thickening (fi gure 1b).
This case highlights the importance of early recognition and initiation of appropriate treatment and supportive care for successful outcome in patients with this potentially fatal toxin-mediated disease. 5 Over the last few years increased numbers of deaths due to infl uenza A and communityacquired S aureus co-infection have been reported, including that of an adult who died from pandemic H1N1 and MRSA co-infection. 6 7 Furthermore, the Centers for Disease Control 
